Data through Oct 29, 2026 Snapshot Oct 29, 7:00 PM ET
CRSP
CRSP
CRISPR Therapeutics
$53.36
+$7.48(+16.31%)•
Brian's position
Shares217.9599
Cost basis$10,000.00
Bought at$45.88
Last close$54.26
Current value$11,631.28
Total return+16.31%
Gene's position
Shares217.9599
Cost basis$10,000.00
Bought at$45.88
Last close$54.26
Current value$11,631.28
Total return+16.31%
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of t…